EpSSG News

06 May 2020


Valencia 2020

SIOP Europe, alongside CCI Europe, has made the difficult decision to postpone the Annual Meeting in Valencia (4-8 May 2020) due to the Coronavirus (COVID-19) pandemic. New dates will be confirmed soon.

Location: Valencia, Spain

Official EpSSG Spring Meeting 2020 within SIOP Europe Annual Meeting Our meeting will take place…
Read more
01 March 2020

Board Meeting in Milan

EpSSG Board meeting in Paris this October
Board meetings have been suspended due to COVID-19. You will get news by email.
Read more
03 February 2020

NEW EpSSG PAPER first of 2020!!

Inflammatory myofibroblastic tumor: The experience of the European paediatric Soft Tissue Sarcoma Study Group (EpSSG)

The European Journal of Cancer recently published the EpSSG experience on inflammatory myofibroblastic tumor (IMT), a rare neoplasm of intermediate malignancy mainly affecting young people. The study reported on 60 patients (59 with localized, 1 with multifocal disease; 40 ALK-positive) and demonstrated the generally good prognosis for this tumor, even in patients with initially unresectable disease and ALK- negative cases. The 5 -year event-free survival (EFS) and overall survival (OS) were 82.9% and 98.1%, respectively.
The study discussed on the role of systemic therapy in patients with unresectable disease, since the panorama of treatments for IMT is rapidly changing due to the availability of ALK (but also ROS1 and NTRK) inhibitors. In the EpSSG series, the overall response to systemic therapy was 64%: 8/10 cases responded to vinblastine-methotrexate chemotherapy, and 5/5 to ALK-inhibitors. This means that chemotherapy is still a valid option (especially with minimal-morbidity options like vinblastine and low- dose methotrexate). On the other hand, the efficacy of targeted inhibitor-based therapies seems to point to their use as the standard of care; nevertheless, many questions remain unanswered concerning the availability and cost of ALK inhibitors, the duration of such treatments, their long-term effects, the onset (and mechanism) of resistance, the role of second-generation ALK inhibitors (and ROS1 and NTRK inhibitors), the treatment of ALK-negative patients, and so on. Larger studies involving both pediatric and adult patients are needed to clarify all these aspects.

Read more
19 December 2019

Welcome to our New Chair Dr. JHM Hans Merks and to the New Board members

New Chair Dr. JHM Hans Merks and Prof. Gianni bisogno
Dr. Hans Merks, member and Association's co-founder became the new chair replacing Prof. Gianni…
Read more
04 December 2019



London December (4), 5-6, 2019

Location: Allen & Overy offices, London, United Kingdom

Official EpSSG Winter Meeting 2019 Our meeting will take place at the Allen & Overy Offices in…
Read more
27 May 2019

Annual REPORT 2018

This report summarises the main EpSSG activities that have been developed in 2018. Importantly, we have had the opportunity to welcome parents of sarcoma patients to collaborate with us and support the development of our activities since 2016.
Further information is available on the EpSSG website: www.epssgassociation.it

Read more